AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06045403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Issuing health risk warning for a heat or cold
Description: Whenever a health risk warning for a heat or cold is issued, only the elderly in the combined intervention group will be alerted to the early warning information through the digital heat or cold health risk early warning tool.
Study NCT06045403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A digital heat or cold health risk early warning tool
Description: A WeChat mini-program provides real-time updates on early warnings and health advisories.
Study NCT06045403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perform daily self-monitoring of their BP and ECG
Description: Participants in the self-monitoring alone group were instructed to self-measure their BP three times each morning (from 6:00 a.m. to 8:00 a.m.) and evening (from 6:00 p.m. to 8:00 p.m.) at home, and to self-administer ECG measurements twice during the same morning and evening timeframes.
Study NCT06045403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-monitoring blood pressure and ECG device
Description: Devices for self-monitoring blood pressure and electrocardiography (ECG).
Study NCT06277323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly report card intervention
Description: The investigators will increase the frequency (monthly instead of quarterly) and enhance the content of the performance feedback emails sent to cardiologists (i.e., behaviorally-informed).
Study NCT06450444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRIMUS
Description: The Salvia PRIMUS System is designed to provide subcutaneous neurostimulation to the branches of the trigeminal and occipital nerves.
Study NCT05386134 — intervention group
Intervention type: DEVICE
Intervention: Adaptive Optics Retinal Camera
Description: The rtx1 is a non-invasive device functions without making contact with the eye. The fundus of the patient's eye is illuminated with the IR light emitted from the illumination optical system. The device is comprised of an optoelectronic sensor (OES) that measures the optical defects, software that calculates the necessary corrections and a deformable mirror (DM) that constantly adapts its shape to restore the image's clarity. The digital camera, which is built into the instrument, receives the images and then the images are recorded in the computer hard disk. The AO image software registers and averages the captured image series in order to reduce noise and produce a final enhanced image. The rtx1 integrates AO technology in a flood illumination imaging system and enables visualizing the retina with a high transverse optical resolution of 250 line-pairs per millimeter.
Study NCT04554914 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tabelecleucel
Description: Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
Study NCT05720585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention of mobile health application
Description: According to the contents of the Subjective Memory Complaint (SMC) application intervention program for the older adults previously formulated, the intervention time and the frequency (30min / time, once a week) of each training module and other contents were determined. The application will be implemented and lasted for a total of 1 month.
Study NCT06155383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m2, Bid orally, D1-14, every 3 weeks
Study NCT06155383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000 mg/m2, Bid orally, D1-14, every 3 weeks
Study NCT06155383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 130 mg/m2, intravenous infusion, D1, every 3 weeks
Study NCT06155383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: 130 mg/m2, intravenous infusion, D1, every 3 weeks
Study NCT06155383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin
Description: 2.5 mg/kg, intravenous infusion, D1, every 2 weeks
Study NCT06155383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 3.0 mg/kg, intravenous infusion, D1, every 2 weeks
Study NCT05178121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eLearning Training in Suicide Safety Planning
Description: The training includes a web-based didactic in suicide safety planning, interactive practice in counseling microskills with a chat bot, role-playing safety planning with a standardized patient, and reviewing automated feedback on safety planning counseling skills generated from a computer coding system.
Study NCT05164874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Mammography Unit
Description: The main intervention will be a proposition for an appointment at the MMU in complement to the current OBCS
Study NCT05681039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Given by IV (vein)
Study NCT05681039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given by IV (vein)
Study NCT05681039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: after care from surgery
Study NCT05681039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Quality of life
Study NCT05681039 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given by IV (vein)
Study NCT05681039 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given by IV (vein)
Study NCT06019845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAGiC™
Description: Robotic magnetic radiofrequency (RF) ablation catheter
Study NCT06277323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storyboard intervention
Description: The visibility of the care gap banner in the electronic health record (EHR) upon patient encounter will be enhanced.
Study NCT06215989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine Pill
Description: Colchicine 0.5mg once daily will be given on the basis of standard treatment of ACS recommended by guidelines
Study NCT06215989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one tablet once daily will be given on the basis of standard treatment of ACS recommended by guidelines
Study NCT06453122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral care
Description: The intervention group procedure will be carried out in the same way and frequency of the control group, however, replacing the chlorhexidine solution 0.12% for mineral water. Oral hygiene will be carried out by the nursing team, which will be blind to the indices to be evaluated. The team will be previously trained to carry out hygiene procedures by the team of ICU dental surgeons.
Study NCT06453122 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Oral care
Description: The intervention group procedure will be carried out in the same way and frequency of the control group, however, replacing the chlorhexidine solution 0.12% for mineral water. Oral hygiene will be carried out by the nursing team, which will be blind to the indices to be evaluated. The team will be previously trained to carry out hygiene procedures by the team of ICU dental surgeons.
Study NCT05297474 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: No intervention was performed in this study.
Study NCT06197555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Monofluorophosphate
Description: Test toothpaste, participants will brush selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute. The method of application of these agents will be the fingertip method. Patients continued to use the paste twice daily, morning and evening, for 16 weeks.
Study NCT06197555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stannous Fluoride
Description: Test toothpaste, participants will brush selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute. The method of application of these agents will be the fingertip method. Patients continued to use the paste twice daily, morning and evening, for 16 weeks.
Study NCT06197555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nano-Hydroxyapatite
Description: Test toothpaste, participants will brush selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute. The method of application of these agents will be the fingertip method. Patients continued to use the paste twice daily, morning and evening, for 16 weeks.
Study NCT06197555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 8% Arginine & Calcium Carbonate
Description: Test toothpaste, participants will brush selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute. The method of application of these agents will be the fingertip method. Patients continued to use the paste twice daily, morning and evening, for 16 weeks.
Study NCT04569500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PETAL program
Description: patients and their close relations will benefit from the therapeutic education program PETAL in order to accompany them throughout their experience of laryngectomy and to reduce its impact on social and professional aspects of life.
Study NCT05882474 — intervention group
Intervention type: DEVICE
Intervention: PaCO2
Description: Level of partial pressure of carbon dioxide
Study NCT06172907 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Young Adults Coping with Cancer Together Intervention
Description: This intervention is based on cognitive-behavioral therapy and couples' therapy. It aims to improve cancer and caregiving-related self-efficacy and coping, as well as promote relationship maintenance in context of cancer. The intervention will be delivered by a trained mental health practitioner and include didactics, experiential exercises, and home practice.
Study NCT06475937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM001
Description: Subjects may continue to receive DM001 (with an increased dose that has been assessed as safe in the dose-escalation period) once every 3 weeks (Q3W) for a total of 6 cycles at the discretion of the investigators, until unacceptable toxicity, progressive disease (PD), or withdrawal of consent.
Study NCT06068881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazverik (Tazemetostat)
Description: Oral Tablet
Study NCT04210284 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure
Description: Ensure Max Protein Shake is an over the counter available drinkable nutritional supplement. Per serving, it contains:~* 160 Calories, 20 from fat~* 2g Total fat~* 0.5g Saturated fat~* 20mg Cholesterol~* 135mg Sodium~* 170mg Potassium~* 19g Total carbohydrate~* \<1g Fiber~* 4g Sugar~* 16g Protein~Participants will receive Ensure High Protein for 2 weeks pre- and 4 weeks post-operatively. These patients will be instructed to consume 1 serving (16fl oz) of Ensure High Protein daily. They will be provided with this product at a pre-operative clinical visit or have it mailed to their home. Hematologic nutritional values will be measured as specified previously.~Descriptive statistics will be used to report baseline characteristics and primary study objectives. Hematologic outcomes will be compared between the control (NO ENSURE) and oral supplementation (ENSURE) arms for the aforementioned baseline and perioperative variables
Study NCT01539876 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fine needle aspiration assessing tumour TNFa levels
Description: Fine Needle aspiration will be done X5: 1 hr pre-treatment, 1hr post treatment,24 hrs post treatment, 48 hrs post treatment, and following last chemotherapy cycle
Study NCT05716477 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05716477 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study NCT04660344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive 1680 mg intravenously every 4 weeks (Q4W) on Day 1 of each 28-day cycle.
Study NCT04660344 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo intravenously Q4W on Day 1 of each 28-day cycle
Study NCT04761276 — intervention group
Intervention type: DEVICE
Intervention: Surgical implantation of intra ocular lens
Description: Cataract surgery may be indicated when the cataract reduces visual function to a level that interferes with everyday activities of the patient leading the patient to desire a surgical intervention to improve its vision.
Study NCT05075408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Participants will receive 2 subcutaneous injections for a total dose of 30 milligrams (mg) of nemolizumab every 4 weeks (Q4W), with a loading dose of 60 mg at baseline for a period of 12 weeks with an 8 week follow-up.
Study NCT05075408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Participants will receive 2 subcutaneous injections of 30 mg of nemolizumab Q4W starting at baseline for a period of 12 weeks with an 8 week follow-up.
Study NCT05075408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 2 subcutaneous injections of 30 mg of placebo-matched to nemolizumab Q4W for a period of 12 weeks with an 8 week follow-up.
Study NCT05514262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The stress ball
Description: Covid-19 vaccination procedure with individuals in the stress ball group: With this group, a yellow stress ball will be used which is 6cm in diameter, of medium hardness and made of high quality silicone, and which returns to its original shape after being squeezed. The researcher will explain to the individuals in the group how they should use the stress ball five minutes before beginning the vaccination and during the procedure. The individuals will be taught to take the stress ball in their right hand, the side on which the vaccination will not be given, and, counting from one to three, to squeeze and release the ball, continuing until the procedure is finished. It will be explained that during the procedure, they should give their attention to the stress ball and focus on squeezing it.
Study NCT05514262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Buzzy® device
Description: Covid-19 vaccination procedure with individuals in the Buzzy® group: Individuals in this group will use the Buzzy® device. Before the vaccination procedure, the researcher will place the Buzzy® device, which will be at room temperature, on the vaccination site, and it will vibrate in a non-discomforting way for one minute. After this, the Buzzy® device will be removed from the site, and the nurse will perform the vaccination. Because Buzzy® is a device which can be re-used, it will be disinfected after each vaccination procedure, and re-used with other individuals. The Buzzy® device also has ice wings which will not be used in this study, and only the body of the device will be used to provide vibration.
Study NCT05894798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture at point LI 4 in the thumb grip on the upper side of the hand, bilaterally, with a sterile disposable needle of dimension 0.20 x 13 mm. The stitch is approximately three mm deep. The needle is allowed to remain in place for about 30 seconds
Study NCT05687903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-861
Description: TAK-861 oral tablets
Study NCT05517109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemodynamic goal including lower goal of systolic blood pressure
Description: Different hemodynamic goals in different study arms
Study NCT05687903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablets matching TAK-861
Study NCT05687903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral tablets matching TAK-861
Study NCT05982769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance Training 3 times per week
Description: endurance training will be performed from home 3 times per week under the supervision of the research team.
Study NCT03919695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kisoboka: Behavioral and Structural Intervention
Description: The intervention has two components; a structural component and a behavioral component. The intervention draws from behavioral economics and motivational interviewing.~Structural component: This component is about receiving work payments via mobile money instead of cash.~Behavioral component: This component includes feedback on alcohol screening, counseling, client-centered goal setting, self-monitoring, financial literacy training, and text message reminders of life/savings and healthy living goals.
Study NCT03919695 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening and Referral
Description: Alcohol screening and referral and emphasizing the importance of HIV care engagement and ART adherence
Study NCT05507476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin Acetate Nasal, 10 μg/0.1 ml per spray
Description: The patient will receive two puffs of desmopressin acetate 10 µg/puff in the side of the nasal cavity ipsilateral to the obstructed lacrimal duct (20 μg totally) 60 minutes before surgery.
Study NCT05507476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine topical 1:100,000 Nasal Packs
Description: The patient will receive topical 1:100,000 epinephrine in the side of the nasal cavity ipsilateral to the obstructed lacrimal gland via 3 soaked packs placed in the middle meatus for 5 minutes immediately before the start of surgery.
Study NCT05982769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: resistance training will be performed from home 2 times per week under the supervision of the research team.
Study NCT05982769 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: continue usual activity
Study NCT05494424 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT)
Description: Goal Management Training is a cognitive rehabilitation intervention that relies on metacognitive strategies to reengage top-down attention processes, in addition to teaching problem-solving techniques, attempting to address executive dysfunctions.
Study NCT06135298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OSTEOSYNTHESIS
Description: Routine procedure for anesthesia and infection prophylaxis according to written instructions will be followed in every patient. The patient will be operated supine with the fractured leg positioned in traction table. The hip region is scrubbed and dressed in sterile drapes. Using standard technique, a nail is inserted into the intramedullary canal after fracture reduction. To insert the helical blade in the femoral neck, 2.0 mm diameter guide wire is first placed in the femoral neck, checking the fluoroscopic AP and lateral views. The canal is opened using a 10 mm drill bit and the length of helical blade is measured. After the pilot hole is created for the helical blade placement, the hollow helical blade will be inserted to its end position with gentle blows with a hammer.
Study NCT06135298 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OSTEOSYNTHESIS
Description: Routine procedure for anesthesia and infection prophylaxis according to written instructions will be followed in every patient. The patient will be operated supine with the fractured leg positioned in traction table. The hip region is scrubbed and dressed in sterile drapes. Using standard technique, a nail is inserted into the intramedullary canal after fracture reduction. To insert the helical blade in the femoral neck, 2.0 mm diameter guide wire is first placed in the femoral neck, checking the fluoroscopic AP and lateral views. The canal is opened using a 10 mm drill bit and the length of helical blade is measured. After the pilot hole is created for the helical blade placement, the hollow helical blade will be inserted to its end position with gentle blows with a hammer.
Study NCT06135298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid (ZA), is a bisphosphonate, and has been shown to reduce the risk of hip fracture by 41% in post-menopausal women. For systemic injection, 5 mg (as per clinical protocol) will be injected intravenously 5 days after surgery, during hospitalization.
Study NCT06135298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: Zoledronic acid (ZA), is a bisphosphonate, and has been shown to reduce the risk of hip fracture by 41% in post-menopausal women. For systemic injection, 5 mg (as per clinical protocol) will be injected intravenously 5 days after surgery, during hospitalization.